Through its research collaborations with various academic and medical facilitates, AXIM is working with an enzyme called “QSOX1” in both its clinical and diagnostic research.
Research suggests a chemical compound that inhibits QSOX1 could be an oncology drug. Axim has discovered SBI-183 to be such a drug.
BIOMARKER – DIAGNOSTIC TEST
Using proprietary polyclonal antibodies in collaboration with world-renowned research and academic centers, we have introduced a prototype diagnostic test that measures levels of QSOX1-L in blood and filed for patent protection.
AXIM Biotechnologies was one of the first companies to identify the potential therapeutic benefits of known cannabinoids CBD, THC and CBG. Since then, AXIM researchers have continued to pursue research on the positive effects of these compounds in treatment of various indications.